A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
- 1 April 2022
- journal article
- editorial
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , 831-834
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our ConstituenciesJACC, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trialThe Lancet, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of Cardiac Failure, 2017
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of Cardiac Failure, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015